Noninvasive Cardiac Imaging

Am Fam Physician. 2007 Apr 15;75(8):1219-1228.

ACF  This article exemplifies the AAFP 2007 Annual Clinical Focus on management of chronic illness.

  Related Editorial

Noninvasive cardiac imaging can be used for the diagnostic and prognostic assessment of patients with suspected or known coronary artery disease. It is central to the treatment of patients with myocardial infarction, coronary artery disease, or acute coronary syndromes with or without angina. Radionuclide cardiac imaging; echocardiography; and, increasingly, cardiac computed tomography and cardiac magnetic resonance imaging techniques play an important role in the diagnosis of coronary artery disease, which is the leading cause of mortality in adults in the United States. Contemporary imaging techniques, with either stress nuclear myocardial perfusion imaging or stress echocardiography, provide a high sensitivity and specificity in the detection and risk assessment of coronary artery disease, and have incremental value over exercise electrocardiography and clinical variables. They also are recommended for patients at intermediate to high pretest likelihood of coronary artery disease based on symptoms and risk factors. Cardiac magnetic resonance imaging and cardiac computed tomography are newly emerging modalities in the evaluation of patients with coronary artery disease. Cardiac magnetic resonance imaging is useful in the assessment of myocardial perfusion and viability, as well as function. It also is considered a first-line tool for the diagnosis of arrhythmogenic right ventricular dysplasia. Cardiac computed tomography detects and quantifies coronary calcium and evaluates the lumen and wall of the coronary artery. It is a clinical tool for the detection of subclinical coronary artery disease in select asymptomatic patients with an intermediate Framingham 10-year risk estimate of 10 to 20 percent. In addition, cardiac computed tomography is evolving as a noninvasive tool for the detection and quantification of coronary artery stenosis. Although guidelines can help with treating patients, treatment ultimately should be tailored to each person based on clinical judgment of the a priori risk of a cardiac event, symptoms, and the cardiac risk profile.

Coronary artery disease (CAD) is the leading cause of mortality in men and women in the United States and claims 500,000 lives each year.1 Establishing the diagnosis, extent, and severity of CAD and determining the potential risk of cardiovascular events are crucial steps toward improving patient outcomes. The use of noninvasive cardiac imaging in the identification of CAD involves techniques that provide images of cardiac structure and increasingly yield physiologic information that assists in management and treatment decisions.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References

Noninvasive cardiac imaging is recommended for patients at an intermediate pretest likelihood of CAD (based on symptoms and cardiac risk factors). Stress SPECT myocardial perfusion imaging or stress echocardiography provide accurate diagnostic and prognostic information in these patients.

A

26

Patients with risk factors and symptoms suggestive of CAD who can exercise should undergo treadmill testing alone or in combination with cardiac imaging because it allows for diagnostic information and the derivation of prognostic data through assessment of exercise capacity.

A

6

Patients with risk factors and symptoms suggestive of CAD who cannot exercise can be stressed with dipyridamole (Persantine) or adenosine (Adenoscan) or may undergo dobutamine (Dobutrex) stress studies, either by cardiac radionuclide imaging or echocardiography.

A

2,4,6

Recent expert consensus documents and prospective studies have suggested the use of calcium scoring in clinically-selected asymptomatic patients who are at intermediate risk of CAD (Framingham risk estimate of 10 to 20 percent).

C

47,50

Cardiac MRI is a further expanding technique that allows assessment of myocardial perfusion and viability and is considered first-line testing for the diagnosis of arrhythmogenic right ventricular dysplasia and for the identification of the course of anomalous coronary arteries. The use of cardiac MRI, however, is limited by cost and availability.

C

50, 53


CAD = coronary artery disease; SPECT = single-photon emission computed tomography; MRI = magnetic resonance imaging.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, see page 1135 or http://www.aafp.org/afpsort.xml.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

View Table

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References

Noninvasive cardiac imaging is recommended for patients at an intermediate pretest likelihood of CAD (based on symptoms and cardiac risk factors). Stress SPECT myocardial perfusion imaging or stress echocardiography provide accurate diagnostic and prognostic information in these patients.

A

26

Patients with risk factors and symptoms suggestive of CAD who can exercise should undergo treadmill testing alone or in combination with cardiac imaging because it allows for diagnostic information and the derivation of prognostic data through assessment of exercise capacity.

A

6

Patients with risk factors and symptoms suggestive of CAD who cannot exercise can be stressed with dipyridamole (Persantine) or adenosine (Adenoscan) or may undergo dobutamine (Dobutrex) stress studies, either by cardiac radionuclide imaging or echocardiography.

A

2,4,6

Recent expert consensus documents and prospective studies have suggested the use of calcium scoring in clinically-selected asymptomatic patients who are at intermediate risk of CAD (Framingham risk estimate of 10 to 20 percent).

C

47,50

Cardiac MRI is a further expanding technique that allows assessment of myocardial perfusion and viability and is considered first-line testing for the diagnosis of arrhythmogenic right ventricular dysplasia and for the identification of the course of anomalous coronary arteries. The use of cardiac MRI, however, is limited by cost and availability.

C

50, 53


CAD = coronary artery disease; SPECT = single-photon emission computed tomography; MRI = magnetic resonance imaging.

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, see page 1135 or http://www.aafp.org/afpsort.xml.

The value of commonly used noninvasive cardiac diagnostic techniques is now well established. Research continues to help develop new techniques and improve existing techniques and applications in the areas of cardiac radionuclide imaging, echocardiography, cardiac computed tomography (CT), and cardiac magnetic resonance imaging (MRI). Current guidelines from national organizations, including the American Heart Association (AHA) and the American College of Cardiology (ACC), provide guidance on the choice and use of imaging modalities in patient populations with and at risk of CAD.27

Initial Evaluation of Patients with Suspected CAD

Evaluation of patient history will reveal the presence of cardiac risk factors, including age, sex, hypertension, diabetes, smoking, physical inactivity, obesity, abnormal lipid profile, and family history in any first-degree female relative 65 years or younger or first-degree male relative 55 years or younger. The presence, character, location, and associated symptoms of chest pain or angina and the precipitating, exacerbating, or alleviating factors should be assessed. The Framingham risk estimate, a global risk score that includes traditional risk factors for CAD, also should be assessed. Based on their Framingham risk score, patients at low risk have a less than 10 percent 10-year CAD risk, patients at intermediate risk have a 10 to 20 percent 10-year CAD risk, and those at high risk have a more than 20 percent 10-year CAD risk. This translates to expected annual rates of CAD death or myocardial infarction (MI) of less than 0.6 percent (low risk), 0.6 percent to 2.0 percent (intermediate risk), and more than 2.0 percent (high risk).8 The online Framingham risk estimate calculator can be found at http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=prof.

Resting 12-lead electrocardiography (ECG) should be performed on all patients with suspected CAD. The presence of left ventricular hypertrophy, ST-segment changes, T-wave changes, diagnostic Q waves in two contiguous leads, and conduction abnormalities (e.g., left bundle branch block) increases the likelihood of CAD.810 Noninvasive cardiac testing is recommended for the symptomatic patient at intermediate risk of CAD, based on the presence of risk factors and symptoms.2,4,6,7 Patients who can exercise should undergo treadmill testing alone or in combination with cardiac imaging because this assessment of exercise capacity yields diagnostic and prognostic data.6

Treadmill testing with exercise ECG is the oldest and most commonly used form of noninvasive cardiac testing in the evaluation of patients with suspected CAD. According to the ACC/AHA exercise testing guidelines, patients should undergo exercise treadmill testing if they are at an intermediate pretest risk of CAD based on symptoms and risk factors, have a normal resting ECG, and are capable of maximal exercise.6 Patients with poor functional capacity on treadmill stress testing (less than five metabolic equivalents) typically will have a poor prognosis.3,11,12

In daily clinical practice, the risk assessment helps determine management. Patients with an increased likelihood of a cardiac event should be referred for testing and more intensive treatment, whereas those at low risk of cardiac events can be treated with medical therapy and risk factor modification and avoid further testing.210,13,14 Figure 17 is an algorithm showing the diagnosis and risk stratification of patients with suspected CAD; it is based on ACC/AHA guidelines for the evaluation of stable angina.

Determining the Diagnosis and Risk Stratification for Patients with Suspected CAD

Figure 1

Algorithm for choosing the appropriate candidate for stress testing in patients with suspected coronary artery disease (CAD). (MI = myocardial infarction; MET = metabolic equivalent; ECG = electrocardiography). Information from reference 7.

View Large

Determining the Diagnosis and Risk Stratification for Patients with Suspected CAD


Figure 1

Algorithm for choosing the appropriate candidate for stress testing in patients with suspected coronary artery disease (CAD). (MI = myocardial infarction; MET = metabolic equivalent; ECG = electrocardiography). Information from reference 7.

Determining the Diagnosis and Risk Stratification for Patients with Suspected CAD


Figure 1

Algorithm for choosing the appropriate candidate for stress testing in patients with suspected coronary artery disease (CAD). (MI = myocardial infarction; MET = metabolic equivalent; ECG = electrocardiography). Information from reference 7.

Cardiac Radionuclide Imaging: SPECT Myocardial Perfusion Imaging

UTILITY AND PATIENT SELECTION

Stress myocardial perfusion imaging with single-photon emission computed tomography (SPECT) uses radioactive tracers to provide information about regional blood flow, coronary artery perfusion, and ventricular function.2 A meta-analysis of 33 studies, which included thallium 201 and technetium tracers, found that nuclear exercise stress imaging for the detection of CAD (50 percent or more stenosis) had an average sensitivity of 87 percent and specificity of 73 percent.2 Pharmacologic stress SPECT myocardial perfusion imaging with vasodilator agents (e.g., adenosine [Adenoscan] and dipyridamole [Persantine]) is often used and has a high diagnostic accuracy in patients with suspected CAD who are incapable of exercise. The overall estimated sensitivity of vasodilator stress is 89 percent with a specificity of 75 percent.2 Vasodilator pharmacologic SPECT has been shown to be more accurate than exercise perfusion imaging in the identification of CAD in patients with a left bundle branch block.

Over the last decade, innovations in myocardial perfusion imaging have resulted in substantial improvements in its accuracy. The lower energy-isotope (thallium 201) is now largely supplanted by the use of technetium-based imaging agents that improve accuracy, particularly with ECG gated SPECT imaging.2 With ECG gated SPECT, image data are acquired in synchrony with the ECG signal, facilitating the evaluation of wall motion and ejection fraction. Recent clinical studies have suggested that technetium agents have better specificity, especially for women with suspected CAD in whom false-positive results caused by breast attenuation and small left ventricular chamber size were common with the use of thallium 201.3,1517

Within the last three years, the validation and addition of attenuation correction techniques to myocardial perfusion imaging have demonstrated improved specificity.2 Overall, in patients with symptoms suggestive of typical or atypical angina, exercise or pharmacologic stress SPECT myocardial perfusion imaging yields a sensitivity for detecting CAD of 85 to 90 percent and a specificity of 80 to 90 percent when gated SPECT is used.2,1517

Myocardial perfusion imaging has been shown to have powerful predictive value for the development of subsequent cardiac death or MI or the need for coronary revascularization. Stress myocardial perfusion imaging provides prognostic information supplemental to that of clinical and exercise ECG variables, and has an excellent negative predictive value for identifying patients at low risk of cardiac events (e.g., death, MI).2 A normal perfusion scan at peak stress is associated with an excellent outcome and a cardiac event rate of less than 1 percent per year. Prognosis worsens relative to the number of vascular territories involved, the extent and severity of defect size, and the degree of reversibility. Additional negative prognostic components include poststress ejection fraction less than 45 percent, end systolic volume more than 70 mL, transient ischemic dilation, and increased lung uptake of thallium 201.2,1822

Recent validations of contemporary computer techniques and protocols have resulted in decreased radiation exposure and shorter imaging times.2,23,24

RECOMMENDATIONS FOR CARDIAC RADIONUCLIDE STRESS TESTING

Table 124,6 lists the guidelines for cardiac radionuclide stress testing. The guidelines are based on evidence or general agreement that a given procedure is useful and effective.

Table 1

Recommended Uses for Cardiac Radionuclide Stress Testing

In patients with an intermediate likelihood or clinical suspicion of CAD when standard exercise testing is likely to be nondiagnostic (e.g., the presence of resting ST-T-wave abnormalities, left bundle branch block, ventricular-paced rhythms, left ventricular hypertrophy, digitalis treatment)

In patients with suspected acute coronary syndrome in the emergency department with nondiagnostic ECG and initial biomarkers

Diagnosis of chronic CAD relating to the diagnosis of symptomatic and select asymptomatic patients with myocardial ischemia; assessment of ventricular performance; identification of lesions causing myocardial ischemia before planning percutaneous intervention; and risk stratification before noncardiac surgery in select patients

Diagnosis, prognosis, and therapy assessment in patients with unstable angina or non-ST-elevation MI; identification of ischemia in the distribution of the culprit lesion or in remote areas; measurement of baseline left ventricular function; and identification of disease severity in patients whose angina is satisfactorily stabilized with medical therapy

Prognosis and risk and therapy assessment after ST-elevation acute MI; assessment of resting right ventricular and left ventricular function; assessment of the presence or extent of stress-induced ischemia; and detection of infarct size and residual viable myocardium

Assessment of interventions in chronic CAD for the presence of restenosis after coronary intervention

Determination of initial left ventricular and right ventricular performance in heart failure; initial evaluation of left ventricular function in patients receiving chemotherapy with doxorubicin (Adriamycin); and assessment of myocardial viability in patients with CAD and left ventricular dysfunction without angina


CAD = coronary artery disease; ECG = electrocardiography; MI = myocardial infarction.

Information from references 2 through 4, and reference 6.

Table 1   Recommended Uses for Cardiac Radionuclide Stress Testing

View Table

Table 1

Recommended Uses for Cardiac Radionuclide Stress Testing

In patients with an intermediate likelihood or clinical suspicion of CAD when standard exercise testing is likely to be nondiagnostic (e.g., the presence of resting ST-T-wave abnormalities, left bundle branch block, ventricular-paced rhythms, left ventricular hypertrophy, digitalis treatment)

In patients with suspected acute coronary syndrome in the emergency department with nondiagnostic ECG and initial biomarkers

Diagnosis of chronic CAD relating to the diagnosis of symptomatic and select asymptomatic patients with myocardial ischemia; assessment of ventricular performance; identification of lesions causing myocardial ischemia before planning percutaneous intervention; and risk stratification before noncardiac surgery in select patients

Diagnosis, prognosis, and therapy assessment in patients with unstable angina or non-ST-elevation MI; identification of ischemia in the distribution of the culprit lesion or in remote areas; measurement of baseline left ventricular function; and identification of disease severity in patients whose angina is satisfactorily stabilized with medical therapy

Prognosis and risk and therapy assessment after ST-elevation acute MI; assessment of resting right ventricular and left ventricular function; assessment of the presence or extent of stress-induced ischemia; and detection of infarct size and residual viable myocardium

Assessment of interventions in chronic CAD for the presence of restenosis after coronary intervention

Determination of initial left ventricular and right ventricular performance in heart failure; initial evaluation of left ventricular function in patients receiving chemotherapy with doxorubicin (Adriamycin); and assessment of myocardial viability in patients with CAD and left ventricular dysfunction without angina


CAD = coronary artery disease; ECG = electrocardiography; MI = myocardial infarction.

Information from references 2 through 4, and reference 6.

Echocardiography and Stress Echocardiography

UTILITY AND PATIENT SELECTION

Two-dimensional echocardiography provides excellent images of the heart and great vessels, as well as the assessment of regional and global left and right ventricular function. Of all the noninvasive techniques, it is the most versatile and provides the most ancillary information at the lowest cost.4 Stress echocardiography with exercise or dobutamine (Dobutrex) can assess for the presence of left ventricular systolic or diastolic dysfunction, valvular heart disease, and the extent of infarction and stress-induced ischemia. Exercise echocardiography may be performed using treadmill, supine bicycle, or upright bicycle. In patients who cannot exercise, dobutamine is the most commonly used pharmacologic stress agent; vasodilator stress echocardiography (with dipyridamole or adenosine) has been reported to have a lower diagnostic sensitivity for single vessel disease.25 Transient regional wall motion abnormality, if visualized in the setting of exercise or dobutamine stress, is a marker of CAD.

Based on data in patients with suspected CAD, stress echocardiography has demonstrated very good diagnostic accuracy for detecting or excluding significant CAD, with a mean sensitivity of 81 percent, a specificity of 86 percent, and overall accuracy of 84 percent.25,26 In patients with suspected CAD who cannot exercise, dobutamine stress echocardiography reliably detects multivessel stenoses with sensitivities in the range of 75 to 93 percent and specificities in the range of 79 to 92 percent.4

In patients with chronic CAD, left ventricular ejection fraction (LVEF) measured at rest has an important impact on prognosis, with increasing mortality associated with declining LVEF.4 For stress echocardiography, the presence or absence of inducible myocardial ischemia is useful for risk stratification in patients with known or suspected CAD. The number of segments with stress-induced wall motion abnormalities has a strong correlation with cardiac events, death, and MI. Negative stress echocardiography generally denotes a low rate of cardiac events.4 Stress echocardiography with exercise or dobutamine is an effective and highly accurate noninvasive means of detecting CAD and risk-stratifying symptomatic patients with an intermediate to high pretest likelihood of CAD.4,2730

A meta-analysis of 1,405 patients compared stress echocardiography with stress myocardial perfusion imaging.31 The study showed that myocardial perfusion imaging (with the use of older techniques) had higher sensitivity (around 87 to 90 percent); however, it had lower specificity than stress echocardiography, which had a specificity of about 85 percent, and stress nuclear perfusion imaging, which had a specificity of about 75 percent.31 For the evaluation of patients with suspsected CAD, local expertise should guide the selection of technique because contemporary techniques of myocardial perfusion imaging have demonstrated improved specificity, with numbers similar to stress echocardiography.2,1517

RECOMMENDATIONS FOR ECHOCARDIOGRAPHY AND STRESS ECHOCARDIOGRAPHY

Table 24 lists the guidelines for echocardiography in the diagnosis of CAD. These guidelines are based on evidence or general agreement that a given procedure is useful and effective.

Table 2

Recommended Uses for Echocardiography and Stress Echocardiography

Diagnosis of underlying cardiac disease in patients with chest pain and clinical evidence of valvular, pericardial, or primary myocardial disease

Assessment of left ventricular function (when needed) to guide institution and modification of drug therapy in patients with known or suspected left ventricular dysfunction

Evaluation of chest pain in patients with suspected acute myocardial ischemia when baseline ECG is nondiagnostic and when study can be obtained during pain or soon after its abatement

Evaluation of chest pain in patients with suspected aortic dissection

Diagnosis of suspected acute ischemia or infarction not evident by standard means

Assessment of functional significance of coronary lesions (if not already known) in planning percutaneous transluminal coronary angioplasty

Assessment of infarct size or extent of jeopardized myocardium

Stress echocardiography is recommended in patients with an intermediate likelihood or clinical suspicion of CAD when standard exercise testing is likely to be nondiagnostic (e.g., the presence of resting ST-T-wave abnormalities, left bundle branch block, ventricular-paced rhythms, left ventricular hypertrophy, digitalis treatment)


ECG = electrocardiography; CAD = coronary artery disease.

Information from reference 4.

Table 2   Recommended Uses for Echocardiography and Stress Echocardiography

View Table

Table 2

Recommended Uses for Echocardiography and Stress Echocardiography

Diagnosis of underlying cardiac disease in patients with chest pain and clinical evidence of valvular, pericardial, or primary myocardial disease

Assessment of left ventricular function (when needed) to guide institution and modification of drug therapy in patients with known or suspected left ventricular dysfunction

Evaluation of chest pain in patients with suspected acute myocardial ischemia when baseline ECG is nondiagnostic and when study can be obtained during pain or soon after its abatement

Evaluation of chest pain in patients with suspected aortic dissection

Diagnosis of suspected acute ischemia or infarction not evident by standard means

Assessment of functional significance of coronary lesions (if not already known) in planning percutaneous transluminal coronary angioplasty

Assessment of infarct size or extent of jeopardized myocardium

Stress echocardiography is recommended in patients with an intermediate likelihood or clinical suspicion of CAD when standard exercise testing is likely to be nondiagnostic (e.g., the presence of resting ST-T-wave abnormalities, left bundle branch block, ventricular-paced rhythms, left ventricular hypertrophy, digitalis treatment)


ECG = electrocardiography; CAD = coronary artery disease.

Information from reference 4.

Cardiac CT: Coronary Calcium Scoring and Noninvasive Coronary Angiography

UTILITY AND PATIENT SELECTION

Cardiac CT detects and quantifies the amount of coronary artery calcium (a marker of CAD burden) using either electron beam tomography or multidetector CT. Coronary artery calcium scores approximate the total atherosclerotic plaque burden and strongly predict future cardiac events.32 In patients with moderate (101 to 400) or higher (over 400) calcium scores, there is a greater prevalence of obstructive coronary disease.3234 Electron beam tomography is established as first-line testing for the detection of coronary artery calcium.

A recent meta-analysis found that even low coronary artery calcium scores (1 to 100) are associated with about twice the risk of CAD events compared with those persons who have no evidence of coronary artery calcium (a summary adjusted relative risk [RR] of 2.1; 95% confidence interval [CI], 1.6 to 2.9).33 Higher scores are associated with a higher relative risk of events (RR, 4.3 to 17.0; 95% CI, 3.1 to 34.0).33 Despite heterogeneity in some studies, the coronary artery calcium score appears to be an independent predictor of CAD events.3237 More recent studies of coronary artery calcium further suggest that these scores predict CAD events; however, the amount of coronary artery calcium does not correlate with the focal stenosis severity of a given lesion.38,39 Therefore, the use of calcium scanning for predicting the necessity of performing angioplasty or bypass surgery is limited.33,34,4044

In addition to the quantification of calcium, a new generation of multislice CT scanners permits the noninvasive acquisition of very high-quality coronary CT angiography. According to a study that evaluated 103 consecutive patients, early generation cardiac CT using 16-slice multidetector CT still performed quite well. When compared with invasive coronary angiography, multidetector CT had a high discriminative power to detect significant obstructive CAD, with sensitivity and specificity in the 90 percent range.45 Multidetector CT does have limitations, including high radiation exposure, the need to administer contrast media, and the need to obtain a heart rate of 60 beats per minute or less; however, a recent study found that 64-slice multidetector CT had a sensitivity for the detection of stenosis of more than 75 percent and a specificity of 97 percent.46

RECOMMENDATIONS FOR CARDIAC CT

Cardiac CT has been demonstrated to provide quantitative measures of calcified and noncalcified coronary artery plaque. Calcified coronary plaque, as determined by cardiac CT, documents the presence of coronary atherosclerosis and identifies persons at elevated risk of MI and cardiovascular death.47 Although a positive calcium scan indicates CAD, often there is no significant stenosis. Therefore, the recent AHA expert consensus document on the assessment of CAD by cardiac CT notes the lack of supportive evidence for the widespread screening for CAD and instead endorses the use of calcium testing as a screening procedure in select groups of patients.47 A number of studies have reported that coronary artery calcium has independent and incremental value when added to clinical or historical data in the estimation of death and nonfatal MI.3239

Recent expert consensus documents have suggested using calcium scoring in clinically selected, asymptomatic patients with an intermediate Framingham 10-year risk estimate of 10 to 20 percent (Figure 248).3,35,4749 In addition, the assessment of coronary calcium may be reasonable in the evaluation of symptomatic patients in the setting of an equivocal stress test.47 The guidelines note that the use of multidetector CT for the noninvasive assessment of lumen coronary artery stenosis in specific circumstances and in specific symptomatic patients is being evaluated and has the potential to change the current diagnostic and management algorithms.47 Based on the current body of evidence, recent appropriateness criteria have been published to guide patient selection for cardiac CT and cardiac MRI.50

Cardiac MRI

UTILITY AND PATIENT SELECTION

Cardiac MRI is a noninvasive technique for evaluating right and left ventricular function, cardiac masses, and congenital heart disease, and for identifying patients with suspected arrhythmogenic right ventricular dysplasia. Cardiac MRI angiography is a standard technique for imaging the aorta and large vessels of the chest and abdomen, as well as assessing the anomalous origin and course of coronary arteries.5153 Cardiac MRI evaluates the presence of CAD by multiple techniques including direct visualization of coronary stenoses; determination of flow within the coronary arteries; evaluation of myocardial perfusion and metabolism; assessment of abnormal wall motion during stress; and identification of infarcted myocardium as well as viable myocardium using delayed hyperenhancement imaging.3,5159

New techniques with cardiac MRI perfusion imaging have demonstrated ability to detect high-grade coronary artery stenoses and to characterize the severity of valvular disease.5559

The use of cardiac MRI in the risk assessment and prognostication of patients with suspected and known CAD was recently evaluated in a study of 279 patients who were referred for dobutamine-atropine cardiac MRI. The presence of inducible ischemia or an LVEF of less than 40 percent were predictors of CAD, death, or MI at an average follow-up of 20 months. Patients who had no evidence of ischemia and who had an LVEF of 40 percent or more had an excellent prognosis in the two years following stress cardiac MRI.60

RECOMMENDATIONS FOR CARDIAC MRI

Studies suggest that cardiac MRI is clinically useful in the assessment of myocardial viability and the evaluation of cardiac structure and function. Recent data demonstrate an evolving role of cardiac MRI in the diagnosis and risk assessment of patients with known or suspected CAD; however, there are limited data to support its use in this setting.50,57

Conclusion

Based on a growing body of evidence, cardiac imaging using contemporary techniques of stress echocardiography or ECG gated SPECT myocardial perfusion imaging provides accurate diagnostic and prognostic information for persons with suspected CAD. Local expertise and availability should guide technique selection.

Research continues to improve existing techniques and applications in the areas of cardiac CT and cardiac MRI. Definitive randomized clinical trial data are not yet available; however, based on existing evidence, many experts advocate that asymptomatic men and women with significant subclinical coronary atherosclerosis should be treated to secondary prevention goals. The asymptomatic patient with a calcium score over 400 has an annual 2 percent risk of CAD death or MI and should be considered at high cardiac risk.3537,39,61 Figure 248 is an algorithm that expands the current clinical guidelines

Testing of Patients at Risk of CAD

Figure 2

Algorithm for testing of asymptomatic and symptomatic patients at risk of coronary artery disease (CAD), including detection of subclinical and obstructive coronary disease. (CT = computed tomography; ECG = electrocardiography; SPECT = single-photon emission computed tomography; MRI = magnetic resonance imaging.)

*-Cardiac MRI for candidates who are not suitable for echocardiography or SPECT.

Adapted with permission from Shaw LJ, Bairey Merz CN, Pepine CJ, Reis SE, Bittner V, Kelsey SF, et al.; for the WISE investigators. Insights from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol 2006;47(3 suppl):S15.

View Large

Testing of Patients at Risk of CAD


Figure 2

Algorithm for testing of asymptomatic and symptomatic patients at risk of coronary artery disease (CAD), including detection of subclinical and obstructive coronary disease. (CT = computed tomography; ECG = electrocardiography; SPECT = single-photon emission computed tomography; MRI = magnetic resonance imaging.)

*-Cardiac MRI for candidates who are not suitable for echocardiography or SPECT.

Adapted with permission from Shaw LJ, Bairey Merz CN, Pepine CJ, Reis SE, Bittner V, Kelsey SF, et al.; for the WISE investigators. Insights from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol 2006;47(3 suppl):S15.

Testing of Patients at Risk of CAD


Figure 2

Algorithm for testing of asymptomatic and symptomatic patients at risk of coronary artery disease (CAD), including detection of subclinical and obstructive coronary disease. (CT = computed tomography; ECG = electrocardiography; SPECT = single-photon emission computed tomography; MRI = magnetic resonance imaging.)

*-Cardiac MRI for candidates who are not suitable for echocardiography or SPECT.

Adapted with permission from Shaw LJ, Bairey Merz CN, Pepine CJ, Reis SE, Bittner V, Kelsey SF, et al.; for the WISE investigators. Insights from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol 2006;47(3 suppl):S15.

The Authors

AMGAD N. MAKARYUS, M.D., is currently an advanced fourth-year cardiovascular imaging fellow at Columbia-Presbyterian Medical Center in New York, N.Y. At the time of writing this manuscript, Dr. Makaryus was a third-year cardiology fellow at North Shore University Hospital, North Shore-Long Island Jewish Health System. He received his medical degree from the State University of New York at Brooklyn College of Medicine and completed an internal medicine residency and a cardiology fellowship at the North Shore University Hospital, North Shore-Long Island Jewish Health System.

RITA F. REDBERG, M.D., M.SC., F.A.C.C., is a professor of medicine and director of the Women’s Cardiovascular Services at the University of California, San Francisco National Center of Excellence in Women’s Health. She received her medical degree from the University of Pennsylvania School of Medicine in Philadelphia. Dr. Redberg completed an internal medicine residency and a cardiology fellowship at the Columbia-Presbyterian Medical Center and a noninvasive cardiology fellowship at Mt. Sinai Medical Center in New York, N.Y.

LESLEE J. SHAW, PH.D., is the director of outcomes research and a professor of medicine at Emory University School of Medicine in Atlanta, Ga. At the time of writing this manuscript, Dr. Shaw was the director of outcomes research at Cedars-Sinai Medical Center in Los Angeles, Calif. She received her Ph.D. from St. Louis (Mo.) University and completed a clinical research fellowship at Duke University Medical School in Durham, N.C.

Address correspondence to Jennifer H. Mieres, M.D., Director of Nuclear Cardiology, New York University School of Medicine, 550 First Ave., TCH-2 Room HW 246, New York, NY (e-mail: Jennifer.mieres@med.nyu.edu). Reprints are not available from the authors.

Author disclosure: Dr. Mieres has received research and grant support from General Electric Healthcare and is on the speaker’s bureau for Astellas Pharma USA, Inc.

Dr. Redberg has received research and grant support from the Robert Wood Johnson Foundation and The Flight Attendant Medical Research Institute.

Dr. Shaw has received grant support from BMS-Medical Imaging, General Electric Healthcare, Astellas Pharma USA, Inc., and King Pharmaceuticals, and is on the speaker’s bureau for Astellas Pharma USA, Inc.

Dr. Makaryus has nothing to disclose.

REFERENCES

1. American Heart Association. Heart disease and stroke statistics - 2006 update. Dallas, Tex.: American Heart Association, 2006. Accessed December 13, 2006 at: http://www.americanheart.org/downloadable/ heart/1136308648540Statupdate2006.pdf.

2. Klocke FJ, Baird MG, Lorell BH, Bateman TM, Messer JV, Berman DS, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radio-nuclide imaging—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging) Circulation. 2003;108:1404-18

3. Mieres JH, Shaw LJ, Arai A, Budoff MJ, Flamm SD, Hundley WG, et al. Role of noninvasive testing in the clinical evaluation of women with suspected coronary artery disease: consensus statement from the Cardiac Imaging Committee, Council on Clinical Cardiology, and the Cardiovascular Imaging and Intervention Committee, Council on Cardiovascular Radiology and Intervention, American Heart Association Circulation. 2005;111:682-96

4. Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography) Circulation. 2003;108:1146-62

5. O’Rourke RA, Brundage BH, Froelicher VF, Greenland P, Grundy SM, Hachamovitch R, et al. American College of Cardiology/American Heart Association Expert Consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease Circulation. 2000;102:126-40

6. Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines) Circulation. 2002;106:1883-92

7. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina) J Am Coll Cardiol. 2003;41:159-68

8. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories Circulation. 1998;97:1837-47

9. Califf RM, Armstrong PW, Carver JR, D’Agostino RB, Strauss WE. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management J Am Coll Cardiol. 1996;27:1007-19

10. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology Circulation. 1999;100:1481-92

11. Von Dras DD, Siegler IC, Williams RB, Clapp-Channing N, Haney TL, Mark DB. Surrogate assessment of coronary artery disease patients’ functional capacity Soc Sci Med. 1997;44:1491-502

12. Gulati M, Black HR, Shaw LJ, Arnsdorf MF, Merz CN, Lauer MS, et al. The prognostic value of a nomogram for exercise capacity in women N Engl J Med. 2005;353:468-75

13. Douglas PS. Is noninvasive testing for coronary artery disease accurate? Circulation. 1997;95:299-302

14. Nishime EO, Cole CR, Blackstone EH, Pashcow FJ, Lauer MS. Heart rate recovery and treadmill exercise score as predictors of mortality in patients referred for exercise ECG JAMA. 2000;284:1392-8

15. Taillefer R, DePuey EG, Udelson JE, Beller GA, Latour Y, Reeves F. Comparative diagnostic accuracy of Tl-201 and Tc-99m sestamibi SPECT imaging (perfusion and ECG-gated SPECT) in detecting coronary artery disease in women J Am Coll Cardiol. 1997;29:69-77

16. Amanullah AM, Berman DS, Hachamovitch R, Kiat H, Kang X, Friedman JD. Identification of severe or extensive coronary artery disease in women by adenosine technetium-99m sestamibi SPECT Am J Cardiol. 1997;80:132-7

17. Santana-Boado C, Candell-Riera J, Castell-Conesa J, Aguade-Bruix S, Garcia-Burillo A, Canela T, et al. Diagnostic accuracy of technetium-99m-MIBI myocardial SPECT in women and men J Nucl Med. 1998;39:751-5

18. Marwick TH, Shaw LJ, Lauer MS, Kesler K, Hachamovitch R, Heller GV, et al. The noninvasive prediction of cardiac mortality in men and women with known or suspected coronary artery disease. Economics of Noninvasive Diagnosis (END) Study Group Am J Med. 1999;106:172-8

19. Sharir T, Germano G, Kavanagh PB, Lai S, Cohen I, Lewin HC, et al. Incremental prognostic value of post-stress left ventricular ejection fraction and volume by gated myocardial perfusion single photon emission computed tomography Circulation. 1999;100:1035-42

20. Giri S, Shaw LJ, Murthy DR, Travin MI, Miller DD, Hachamovitch R, et al. Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease Circulation. 2002;105:32-40

21. Berman DS, Kang X, Hayes SW, Friedman JD, Cohen I, Abidov A, et al. Adenosine myocardial perfusion SPECT in women compared with men: impact of diabetes mellitus on incremental prognostic value and effect on patient management J Am Coll Cardiol. 2003;41:1125-33

22. Shaw LJ, Iskandrian AE. Prognostic value of stress gated SPECT J Nucl Cardiol. 2004;11:171-85

23. Heller GV, Links J, Bateman TM, Ziffer JA, Ficaro E, Cohen MC, et al. American Society of Nuclear Cardiology and Society of Nuclear Medicine joint position statement: attenuation correction of myocardial perfusion SPECT scintigraphy J Nucl Cardiol. 2004;11:229-30

24. Heller GV, Bateman TM, Johnson LL, Cullom SJ, Case JA, Galt JR, et al. Clinical value of attenuation correction in stress–only Tc-99m sestamibi SPECT imaging J Nucl Cardiol. 2004;11:273-81

25. Kim C, Kwok YS, Heagert P, Redberg R. Pharmacologic stress testing for coronary artery disease: a meta-analysis Am Heart J. 2001;142:934-44

26. Severi S, Picano E, Michelassi C, Lattanzi F, Landi P, Distante A, et al. Diagnostic and prognostic value of dipyridamole echocardiography in patients with suspected coronary artery disease. Comparison with exercise electrocardiography Circulation. 1994;89:1160-73

27. Kuntz KM, Fleischmann KE, Hunink MG, Douglas PS. Cost-effectiveness of diagnostic strategies for patients with chest pain Ann Intern Med. 1999;130:709-18

28. Arruda-Olson AM, Juracan EM, Mahoney DW, McCully RB, Roger VL, Pellikka PA. Prognostic value of exercise echocardiography in 5,798 patients: is there a gender difference? J Am Coll Cardiol. 2002;39:625-31

29. Marwick TH, Shaw L, Case C, Vasey C, Thomas JD. Clinical and economic impact of exercise electrocardiography and exercise echocardiography in clinical practice Eur Heart J. 2003;24:1153-63

30. Lorenzoni R, Cortigiani L, Magnani M, Desideri A, Bigi R, Manes C, et al. Cost-effectiveness analysis of noninvasive strategies to evaluate patients with chest pain J Am Soc Echocardiogr. 2003;16:1287-91

31. Schinkel AF, Bax JJ, Geleijnse ML, Boersma E, Elhendy A, Roelandt JR, et al. Noninvasive evaluation of ischaemic heart disease: myocardial perfusion imaging or stress echocardiography? Eur Heart J. 2003;24:789-800

32. Budoff MJ, Achenbach S, Duerinckx A. Clinical utility of computed tomography and magnetic resonance techniques for noninvasive coronary angiography J Am Coll Cardiol. 2003;42:1867-78

33. Pletcher MJ, Tice JA, Pignone M, Browner WS. Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis Arch Intern Med. 2004;164:1285-92

34. Raggi P, Callister TQ, Cooil B, He ZX, Lippolis NJ, Russo DJ, et al. Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography Circulation. 2000;101:850-5

35. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals [published correction appears in JAMA 2004;291:563] JAMA. 2004;291:210-5

36. Kondos GT, Hoff JA, Sevrukov A, Daviglus ML, Garside DB, Devries SS, et al. Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5,635 initially asymptomatic low- to intermediate-risk adults Circulation. 2003;107:2571-6

37. Shaw LJ, Raggi P, Schisterman E, Berman DS, Callister TQ. Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality Radiology. 2003;228:826-33

38. Arad Y, Goodman KJ, Roth M, Newstein D, Guerci AD. Coronary calcification, coronary risk factors, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study J Am Coll Cardiol. 2005;46:158-65

39. Taylor AJ, Bindeman J, Feuerstein I, Cao F, Brazaitis M, O’Malley PG. Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project J Am Coll Cardiol. 2005;46:807-14

40. Wexler L, Brundage B, Crouse J, Detrano R, Fuster V, Maddahi J, et al. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association Writing Group Circulation. 1996;94:1175-92

41. Breen JF, Sheedy PF II, Schwartz RS, Stanson AW, Kaufmann RB, Moll PP, et al. Coronary artery calcification detected with ultrafast CT as an indication of coronary artery disease Radiology. 1992;185:435-9

42. Agatston AS, Janowitz WR, Kaplan G, Gasso J, Hildner F, Viamone M Jr. Ultrafast computed tomography detected coronary calcium reflects the angiography extent of coronary arterial atherosclerosis Am J Cardiol. 1994;74:1272-4

43. Arad Y, Sparado LA, Goodman K, Newstein D, Guerci AD. Prediction of coronary events with electron beam computed tomography J Am Coll Cardiol. 2000;36:1253-60

44. Mautner GC, Mautner SL, Froehlich J, Feuerstein IM, Proschan MA, Roberts WC, et al. Coronary artery calcification: assessment with electron beam CT and histomorphometric correlation Radiology. 1994;192:619-23

45. Hoffman MH, Shi H, Schmitz BL, Schmid FT, Lierberknecht M, Schulze R, et al. Noninvasive coronary angiography with multislice computed tomography [published correction appears in JAMA 2005;294:1208] JAMA. 2005;293:2471-8

46. Leber AW, Knez A, von Ziegler F, Becker A, Nikolaou K, Paul S, et al. Quantification of obstructive and nonobstructive coronary lesions by 64-slice computed tomography: a comparative study with quantitative coronary angiography and intravascular ultrasound J Am Coll Cardiol. 2005;46:147-54

47. Budoff MJ, Achenbach S, Blumenthal RS, Carr JJ, Goldin JG, Greenland P, et al. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology Circulation. 2006;114:1761-91

48. Shaw LJ, Bairey Merz CN, Pepine CJ, Reis SE, Bittner V, Kelsey SF, et al., for the WISE investigators. Insights from the NHLBI-ponsored Women‘s Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol. 2006;47:3 supplS4-S20

49. Taylor AJ, Merz CN, Udelson JE. 34th Bethesda Conference: executive summary—can atherosclerosis imaging techniques improve the detection of patients at risk for ischemic heart disease? J Am Coll Cardiol. 2003;41:1860-2

50. Hendel RC, Patel MR, Kramer CM, Poon M, Hendel RC, Carr JC, et al. ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology J Am Coll Cardiol. 2006;48:1475-97

51. Kim WY, Danias PG, Stuber M, Flamm SD, Plein S, Nagel E, et al. Coronary magnetic resonance angiography for the detection of coronary stenoses N Engl J Med. 2001;345:1863-9

52. Hundley WG, Hillis LD, Hamilton CA, Applegate RJ, Herrington DM, Clarke GD, et al. Assessment of coronary arterial restenosis with phase-contrast magnetic resonance imaging measurements of coronary flow reserve Circulation. 2000;101:2375-81

53. Nagel E, Klein C, Paetsch I, Hettwer S, Schnackenburg B, Wegscheider K, et al. Magnetic resonance perfusion measurements for the noninvasive detection of coronary artery disease Circulation. 2003;108:432-7

54. Schwitter J, DeMarco T, Kneifel S, von Schulthess GK, Jorg MC, Arheden H, et al. Magnetic resonance-based assessment of global coronary flow and flow reserve and its relation to left ventricular functional parameters: a comparison with positron emission tomography Circulation. 2000;101:2696-702

55. Nagel E, Lehmkuhl HB, Bocksch W, Klein C, Vogel U, Frantz E, et al. Noninvasive diagnosis of ischemia-induced wall motion abnormalities with the use of high-dose dobutamine stress MRI: comparison with dobutamine stress echocardiography Circulation. 1999;99:763-70

56. Hundley WG, Hamilton CA, Thomas MS, Herrington DM, Salido TB, Kitzman DW, et al. Utility of fast cine magnetic resonance imaging and display for the detection of myocardial ischemia in patients not well suited for second harmonic stress echocardiography Circulation. 1999;100:1697-702

57. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction N Engl J Med. 2000;343:1445-53

58. Pennell DJ, Sechtem UP, Higgins CB, Manning WJ, Pohost GM, Rademakers FE, et al. Clinical indications for cardiovascular magnetic resonance (CMR): consensus panel report Eur Heart J. 2004;25:1940-65

59. Ray T, Biederman RW, Doyle M, Mankad S. Magnetic resonance imaging in the assessment of coronary artery disease Curr Atheroscler Rep. 2005;7:108-14

60. Hundley WG, Morgan TM, Neagle CM, Hamilton CA, Rerkpattanapipat P, Link KM. Magnetic resonance imaging determination of cardiac prognosis Circulation. 2002;106:2328-33

61. Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabunmi RP, et al. Evidence-based guidelines for cardiovascular disease prevention in women Circulation. 2004;109:672-93


Copyright © 2007 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article